Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05463939
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05461209
- Locations
- πΊπΈ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
π΅π±Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce, Poland
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 810
- Registration Number
- NCT05455320
- Locations
- π―π΅
Chiba Cancer Center, Chiba, Japan
πͺπΈHosp Univ Hm Sanchinarro, Madrid, Spain
πͺπΈHosp Virgen de La Victoria, Malaga, Spain
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Other: Placebo
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 513
- Registration Number
- NCT05455684
- Locations
- π¨πΏ
Narodni ustav dusevniho zdravi, Klecany, Czechia
π¨πΏPraglandia s r o, Prague 5, Czechia
π¨πΏClintrial s r o, Praha 10, Czechia
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05453903
- Locations
- πͺπΈ
Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain
πͺπΈHosp Clinic de Barcelona, Barcelona, Spain
πͺπΈHosp Univ Vall D Hebron, Barcelona, Spain
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT05444530
- Locations
- πΊπΈ
Cleveland Clinic, Cleveland, Ohio, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
π¬π§Churchill Hospital, Oxford, United Kingdom
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT05441501
- Locations
- π¬π§
Royal Marsden Hospital, Sutton, United Kingdom
πΊπΈUniversity Of Minnesota, Minneapolis, Minnesota, United States
πΊπΈSidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
A Study of Daratumumab
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05438043
- Locations
- πΊπΈ
University of Miami Sylvester Cancer Center, Miami, Florida, United States
πΊπΈBarnes-jewish Hospital, Saint Louis, Missouri, United States
π§πͺZNA Stuivenberg, Antwerpen, Belgium
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 220
- Registration Number
- NCT05424822
- Locations
- π¦πΊ
The Alfred Hospital, Melbourne, Australia
π«π·Institut de Cancerologie Strasbourg Europe ICANS, Strasbourg, France
π¨π³Sun Yat Sen University Cancer Center, Guangzhou, China
A Single and Multiple Ascending Dose Study of JNJ-64457744
- Conditions
- Hepatitis B, ChronicHealthy
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05423106
- Locations
- π³πΏ
New Zealand Clinical Research, Grafton, New Zealand